ARCHIVES

Phase II Imbruvica Trial Shows 47% of MCL Patients Alive at 27-Month Median Follow-up

This article is from The Cancer Letter archive.

Vol. 37 No. 12 | December 26, 2014

Download PDF Visit The Full Archive

Related Articles

FDA Oncology Division Director Says Goal to Make Review Process “Predictable”

August 2, 1996

Litton’s Government Contracts Status Under Review

September 6, 1985

Broder Emerges As National Leader In ASCO Talk, Calls For Faster Reporting Of Clinical

June 2, 1989

Vanderbilt-Ingram Cancer Center Wins NCI’s Comprehensive Designation.

March 16, 2001

New Community Center Assnt. Determined To Improve Quality Of Care “With Or Without” NCI Assistance

September 27, 1974

If You Were On ODAC: Experts Suggest Questions For May 10 Advisory Meeting.

March 16, 2007